Name (Synonyms) | Correlation | |
---|---|---|
drug8 | 14C-lazertinib Wiki | 0.58 |
drug1356 | Tele-medicine platform Wiki | 0.58 |
drug381 | Covid-19 + patients Wiki | 0.58 |
Name (Synonyms) | Correlation | |
---|---|---|
D054143 | Heart Failure, Systolic NIH | 0.58 |
D000787 | Angina Pectoris NIH | 0.58 |
D054058 | Acute Coronary Syndrome NIH | 0.41 |
D003327 | Coronary Disease NIH | 0.33 |
D003324 | Coronary Artery Disease NIH | 0.33 |
D002318 | Cardiovascular Diseases NIH | 0.28 |
D009203 | Myocardial Ischemia NIH | 0.26 |
D013577 | Syndrome NIH | 0.07 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.03 |
D018352 | Coronavirus Infections NIH | 0.03 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0001635 | Congestive heart failure HPO | 1.00 |
HP:0001681 | Angina pectoris HPO | 0.58 |
HP:0001677 | Coronary artery atherosclerosis HPO | 0.33 |
HP:0001626 | Abnormality of the cardiovascular system HPO | 0.30 |
HP:0001658 | Myocardial infarction HPO | 0.29 |
There are 3 clinical trials
Management of known patients with cardiovascular disease (in particular the whole spectrum of atherosclerotic ischaemic coronary artery disease, essential hypertension under treatment, and also patients with chronic heart failure under medication) and with other associated chronic pathologies, with obvious effects on the management of the pandemic with modern / distance means (e-Health) of patients at high risk of mortality in contact with coronavirus. Given the Covid-19 Pandemic, all the above complex cardiovascular patients are under the obligation to stay in the house isolated and can no longer come to standard clinical and paraclinical monitoring and control visits. Therefore, a remote management solution (tele-medicine) of these patients must be found. The Investigators endeavour is to create an electronic platform to communicate with these patients and offer solutions for their cardiovascular health issues (including psychological and religious problems due to isolation). The Investigators intend to create this platform for communicating with a patient and stratify their complaints in risk levels. A given specialist will sort and classify their needs on a scale, based on specific algorithms (derived from the clinical European Cardiovascular Guidelines), and generate specific protocols varying from 911 like emergencies to cardiological advices or psychological sessions. These could include medication changing of doses, dietary advices or exercise restrictions. Moreover, in those patients suspected of COVID infection, special assistance should be provided per protocol.
Description: Development of an electronic (e-HEALTH) framework structure for management of patients with known cardiovascular disease in COVID19 pandemic social context
Measure: Providing a special electronic platform (e-health) for remote managing cardiovascular outpatients Time: 6 monthsDescription: patients come into direct contact with the case coordinator, who provides ongoing assistance, including for connecting to devices that ensure real-time data transmission and directing to specialist teams that establish stage diagnosis and management / therapy behavior (including adjustment). doses, decisions to discontinue medication or to add medication);
Measure: Number of patients included in this platform Time: 6 monthsDescription: Will be the number of sessions per patient multiplied with the number of patients included
Measure: Number of consultations/sessions given Time: 6 monthsBackground: Coronavirus disease (COVID-19) is a tremendous challenge the modern world has never seen before and is overwhelming the capacities of healthcare systems worldwide. Patients with cardiovascular diseases, heart failure in particular, and cardiovascular risk factors seem to be at a very high risk if affected by COVID-19 - and vice versa there are more and more reports of cardiac manifestations with the viral disease. Aim: The purpose of the study is to characterise the clinical course of adult inpatients with COVID-19 and concomitant cardiovascular affection in a worldwide, multicentre PCHF registry. Methods: Retrospective and prospective data analysis. Data on demographic, clinical, selected laboratory, electrocardiography and echocardiography parameters, treatment and outcome will be collected. The principal investigator provides dedicated electronic case report form. The primary outcome is in-hospital mortality. The secondary endpoints will be ICU length of stay, hospital length of stay, the need and duration of invasive mechanical ventilation, cardiovascular hospitalisation after 3 and 6 months from index hospitalisation, all-cause and cardiovascular mortality after 3 and 6 months from index hospitalisation.
Description: All-cause and cardiovascular mortality during index hospitalization.
Measure: In-hospital mortality. Time: Hospitalization period, assessed up to 30 daysDescription: The duration of hospitalization on the intensive care unit.
Measure: The length of stay in the intensive care unit. Time: Hospitalization period in the ICU, assessed up to 30 daysDescription: The total length of stay in the hospital.
Measure: The duration of hospitalization. Time: Hospitalization period, assessed up to 30 daysThe role of ECMO in the treatment of patients with severe COVID-19 (Acute Respiratory Distress Syndrome (ARDS) and/or acute refractory heart failure) is not yet known. The present study will aim to report the results of the ECMO management of the most severe forms of COVID-19 through the first French ECMO registry.
Description: Hospital mortality
Measure: Hospital mortality Time: up to 90 daysDescription: Mortality Day 28
Measure: Mortality Day 28 Time: Day 28Description: Mortality Day 90
Measure: Mortality Day 90 Time: Day 90Description: Ventilator-free days
Measure: Ventilator-free days Time: Day 28Description: ICU-free days
Measure: Intensive care unit-free days Time: Day 28Description: Hospital-free days
Measure: Hospital-free days Time: Day 28